B cell depletion in the treatment of multiple sclerosis

References

• Thompson AJ, Baranzini SE, Geurts J, et al. Multiple sclerosis. Lancet. 2018;391:1622–1636.
   PubMed Web of Science ®Google Scholar
• Svendsen B, Myhr KM, Nyland H, et al. The cost of multiple sclerosis in Norway. Eur J Health Econ. 2012;13:81–91.
   PubMed Web of Science ®Google Scholar
• Svendsen B, Grytten N, Bø L, et al. The economic impact of multiple sclerosis to the patients and their families in Norway. Eur J Health Econ. 2018 [cited 2018 Apr 21]. DOI:10.1007/s10198-018-0971-5.
   PubMed Web of Science ®Google Scholar
• Grytten Torkildsen N, Lie SA, Aarseth JH, et al. Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway. Mult Scler. 2008;14:1191–1198.
   PubMed Web of Science ®Google Scholar
• Torkildsen O, Myhr KM, Bø L. Disease-modifying treatments for multiple sclerosis - a review of approved medications. Eur J Neurol. 2016;23(Suppl 1):18–27.
   PubMed Web of Science ®Google Scholar
• Ghadiri M, Rezk A, Li R, et al. Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis. Neurol Neuroimmunol Neuroinflamm. 2017;4:e340.
   PubMed Web of Science ®Google Scholar
• Berger JR. Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord. 2017;12:59–63.
   PubMed Web of Science ®Google Scholar
• Alstadhaug KB, Myhr KM, Rinaldo CH. Progressive multifocal leukoencephalopathy. J Norw Med Assoc. 2017;137.
   Google Scholar
• Greenfield AL, Hauser SL. B-cell therapy for multiple sclerosis: entering an era. Ann Neurol. 2018;83:13–26.
   PubMed Web of Science ®Google Scholar
• Grebenciucova E, Berger JR. Progressive multifocal leukoencephalopathy. Neurol Clin. 2018;36:739–750.
   PubMed Web of Science ®Google Scholar
• Holmoy T, Ø T, Myhr KM. An update on cladribine for relapsing-remitting multiple sclerosis. Expert Opin Pharmacother. 2017;18:1627–1635.
   PubMed Web of Science ®Google Scholar
• Major EO, Nath A. A link between long-term natalizumab dosing in MS and PML: putting the puzzle together. Neurol Neuroimmunol Neuroinflamm. 2016;3:e235.
   PubMed Web of Science ®Google Scholar
• Holmoy T, von der Lippe H, Leegaard TM. Listeria monocytogenes infection associated with alemtuzumab - a case for better preventive strategies. BMC Neurol. 2017;17:65.
   PubMed Web of Science ®Google Scholar
• Willis MD, Harding KE, Pickersgill TP, et al. Alemtuzumab for multiple sclerosis: long term follow-up in a multi-centre cohort. Mult Scler. 2016;22:1215–1223.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376:221–234.
   PubMed Web of Science ®Google Scholar
• Montalban X, Ahuaer SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376:209–220.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Waubant E, Arnold D, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358:676–688.
   PubMed Web of Science ®Google Scholar
• Hawker K, O’Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66:460–471.
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Lisby S, Grove R, et al. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. Neurology. 2014;82:573–581.
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Grove RA, Austin DJ, et al. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: the MIRROR study. Neurology. 2018;90:e1805–e1814.
   PubMed Web of Science ®Google Scholar
• Berntsson SG, Kristoffersson A, Bostrom I, et al. Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - outlier or predecessor? Acta Neurol Scand. 2018;138:327–331.
   PubMed Web of Science ®Google Scholar
• Spelman T, Frisell T, Piehl F, et al. Comparative effectiveness of rituximab relative to IFN-beta or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Mult Scler. 2018;24:1087–1095.
   PubMed Web of Science ®Google Scholar
• Salzer J, Svenningsson R, Alping P, et al. Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy. Neurology. 2016;87:2074–2081.
   PubMed Web of Science ®Google Scholar
• Alping P, Frisell T, Novakova L, et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann Neurol. 2016;79:950–958.
   PubMed Web of Science ®Google Scholar
• Granqvist M, Boremalm M, Poorghobad A, et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurol. 2018;75:320–327.
   PubMed Web of Science ®Google Scholar
• Alldredge B, Jordan A, Imitola J, et al. Safety and efficacy of rituximab: experience of a single multiple sclerosis center. Clin Neuropharmacol. 2018;41:56–59.
   PubMed Web of Science ®Google Scholar
• de Flon P, Gunnarsson M, Laurell K, et al. Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab. Neurology. 2016;87:141–147.
   PubMed Web of Science ®Google Scholar
• Durozard P, Maarouf A, Boutiere C, et al. Efficacy of rituximab in refractory RRMS. Mult Scler. 2018 [cited 2018 May 1];1352458518772748. DOI:10.1177/1352458518772748
   Web of Science ®Google Scholar
• Damato V, Evoli A, Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol. 2016;73:1342–1348.
   PubMed Web of Science ®Google Scholar
• Lovato L, Willis SN, Rodig SJ, et al. Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis. Brain. 2011;134:534–541.
   PubMed Web of Science ®Google Scholar
• Baranzini SE, Jeong MC, Butunoi C, et al. B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J Immunol. 1999;163:5133–5144.
   PubMed Web of Science ®Google Scholar
• Owens GP, Ritchie AM, Burgoon MP, et al. Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluid. J Immunol. 2003;171:2725–2733.
   PubMed Web of Science ®Google Scholar
• Qin Y, Duquette P, Zhang Y, et al. Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. J Clin Invest. 1998;102:1045–1050.
   PubMed Web of Science ®Google Scholar
• Obermeier B, Lovato L, Mentele R, et al. Related B cell clones that populate the CSF and CNS of patients with multiple sclerosis produce CSF immunoglobulin. J Neuroimmunol. 2011;233:245–248.
   PubMed Web of Science ®Google Scholar
• Obermeier B, Mentele R, Malotka J, et al. Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis. Nat Med. 2008;14:688–693.
   PubMed Web of Science ®Google Scholar
• Molnarfi N, Schulze-Topphoff U, Weber MS, et al. MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J Exp Med. 2013;210:2921–2937.
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Fawaz L, Fan B, et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol. 2010;67:452–461.
   PubMed Web of Science ®Google Scholar
• Li R, Rezk A, Miyazaki Y, et al. Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy. Sci Transl Med. 2015;7:310ra166.
   PubMed Web of Science ®Google Scholar
• Howell OW, Reeves CA, Nicholas R, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain. 2011;134:2755–2771.
   PubMed Web of Science ®Google Scholar
• Serafini B, Rosicarelli B, Magliozzi R, et al. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004;14:164–174.
   PubMed Web of Science ®Google Scholar
• Moreno MA, Or-Geva N, Aftab BT, et al. Molecular signature of Epstein-Barr virus infection in MS brain lesions. Neurol Neuroimmunol Neuroinflamm. 2018;5:e466.
   PubMed Web of Science ®Google Scholar
• Lossius A, Johansen JN, Ø T, et al. Epstein-Barr virus in systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis-association and causation. Viruses. 2012;4:3701–3730.
   PubMed Web of Science ®Google Scholar
• Endriz J, Ho PP, Steinman L. Time correlation between mononucleosis and initial symptoms of MS. Neurol Neuroimmunol Neuroinflamm. 2017;4: e308.
   PubMed Web of Science ®Google Scholar
• Isaacs JD. Antibody engineering to develop new antirheumatic therapies. Arthritis Res Ther. 2009;11(3):225.
   PubMed Web of Science ®Google Scholar
• Rituxan prescribing information.[cited 2018 Nov 5]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103705s5311lbl.pdf; Ocrevus Prescribing Information [Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761053lbl.pdf]; Arzerra Prescribing Information [Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125326lbl.pdf]
   Google Scholar
• Klein C, Lammens A, Schafer W, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. MAbs. 2013;5:22–33.
   PubMed Web of Science ®Google Scholar
• Du J, Wang H, Zhong C, et al. Crystal structure of chimeric antibody C2H7 fab in complex with a CD20 peptide. Mol Immunol. 2008;45:2861–2868.
   PubMed Web of Science ®Google Scholar
• Leandro MJ. B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies. Arthritis Res Ther. 2013;15(Suppl 1):S3.
   PubMed Web of Science ®Google Scholar
• Palanichamy A, Jahn S, Nickles D, et al. Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. J Immunol. 2014;193:580–586.
   PubMed Web of Science ®Google Scholar
• von Essen MR, Ammitzbøll C, Hansen RH, et al. Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis. Brain. 2019;142:120–132.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Marlton P, Vitolo U, et al. Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann Oncol. 2010;21:1870–1876.
   PubMed Web of Science ®Google Scholar
• Pawluczkowycz AW, Beurskens FJ, Beum PV, et al. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol. 2009;83:749–758.
   Google Scholar
• Robak T, Robak E. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs. 2011;25:13–25.
   PubMed Web of Science ®Google Scholar
• Maloney DG. Follicular NHL: from antibodies and vaccines to graft-versus-lymphoma effects. Hematology Am Soc Hematol Educ Program. 2007;226–232.
   PubMedGoogle Scholar
• Genovese MC, Kaine JL, Lowenstein MB, et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008;58:2652–2661.
   PubMed Web of Science ®Google Scholar
• Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572–2581.
   PubMed Web of Science ®Google Scholar
• Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011;378(9805):1779–1787.
   PubMed Web of Science ®Google Scholar
• Highlights of prescribing information: ocrevus. Revised 3/2017. MD, USA: Food and Drug Administration (FDA). Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2017/761053lbl.pdf
   Google Scholar
• Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol. 2008;63:395–400.
   PubMed Web of Science ®Google Scholar
• Cross AH, Stark JL, Lauber J, et al. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol. 2006;180:63–70.
   PubMed Web of Science ®Google Scholar
• Highlights of prescribing information: rituxan. Revised 10/2012. MD, USA: Food and Drug Administration (FDA). Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2012/103705s5367s5388lbl.pdf
   Google Scholar
• Keystone E, Fleischmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007;56:3896–3908.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72:1496–1502.
   PubMed Web of Science ®Google Scholar
• Marcinnò A, Marnetto F, Valentino P, et al. Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm. 2018;5:e498.
   PubMed Web of Science ®Google Scholar
• Gottenberg JE, Ravaud P, Bardin T, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum. 2010;62:2625–2632.
   PubMed Web of Science ®Google Scholar
• Apostaei AJ, Trabalka JR. Review, synthesis, and application of information on the human lymphatic system to radiation dosimetry for chronic lymphocytic leukemia. Oak Ridge, TN: SENES Oak Ridge, Inc; 2010.
   Google Scholar
• Mamani-Matsuda M, Cosma A, Weller S, et al. The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells. Blood. 2008;111:4653–4659.
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 2003;101:466–468.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. U.S. National library of medicine; 2018.
   Google Scholar
• Komori M, Lin YC, Cortese I, et al. Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Ann Clin Transl Neurol. 2016;3:166–179.
   PubMed Web of Science ®Google Scholar
• Vendramin C, Thomas M, Westwood JP, et al. Rituximab-induced acute and delayed serum sickness in thrombotic thrombocytopenic purpura: the role of anti-rituximab antibodies. Br J Haematol. 2018 [cited 2018 Mar 12]. DOI:10.1111/bjh.15177.
   Web of Science ®Google Scholar
• Dunn N, Juto A, Ryner M, et al. Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies. Mult Scler. 2018;24:1224–1233.
   PubMed Web of Science ®Google Scholar
• Baker D, Marta M, Pryce G, et al. Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis. EBioMedicine. 2017;16:41–50.
   PubMed Web of Science ®Google Scholar
• Agius MA, Klodowska-Duda G, Maciejowski M, et al. Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study. Mult Scler. 2017 [cited 2017 Nov 1];1352458517740641. DOI:10.1177/1352458517740641
   Web of Science ®Google Scholar
• Cree BA, Bennett JL, Sheehan M, et al. Placebo-controlled study in neuromyelitis optica-Ethical and design considerations. Mult Scler. 2016;22:862–872.
   PubMed Web of Science ®Google Scholar
• Kappos L, Hartung HP, Freedman MS, et al. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Neurol. 2014;13:353–363.
   PubMed Web of Science ®Google Scholar
• Montalban X, Weber MS, Staikov I, et al. Primary analysis of a randomised, placebo-controlled, phase 2 study of the Bruton’s tyrosine kinase inhibitor evobrutinib (M2951) in patients with relapsing multiple sclerosis. Mult Scler J. 2018;4:984–985.
   Google Scholar
• Gelfand JM, Cree BAC, Hauser SL. Ocrelizumab and other CD20(+) B-cell-depleting therapies in multiple sclerosis. Neurotherapeutics. 2017;14:835–841.
   PubMed Web of Science ®Google Scholar
• Monaco WE, Jones JD, Rigby WF. Rituximab associated late-onset neutropenia-a rheumatology case series and review of the literature. Clin Rheumatol. 2016;35:2457–2462.
   PubMed Web of Science ®Google Scholar
• Rissanen E, Remes K, Airas L. Severe neutropenia after rituximab-treatment of multiple sclerosis. Mult Scler Relat Disord. 2018;20:3–5.
   PubMed Web of Science ®Google Scholar
• Mok CC. Rituximab for the treatment of rheumatoid arthritis: an update. Drug Des Devel Ther. 2013;8:87–100.
   PubMed Web of Science ®Google Scholar
• Pyrpasopoulou A, Douma S, Vassiliadis T, et al. Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis. Rheumatol Int. 2011;31:403–404.
   PubMed Web of Science ®Google Scholar
• Arkema EV, van Vollenhoven RF, Askling J, et al. Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: a national population-based study. Ann Rheum Dis. 2012;71:1865–1867.
   PubMed Web of Science ®Google Scholar
• Wadstrom H, Frisell T, Askling J. Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: a nationwide cohort study from Sweden. JAMA Intern Med. 2017;177:1605–1612.
   PubMed Web of Science ®Google Scholar
• Alping P, Piehl F, Frisell T. Cancer risk among Swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab. Mult Scler J. 2018;24:36.
   PubMedGoogle Scholar
• Das G, Damotte V, Gelfand JM, et al. Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD. Neurol Neuroimmunol Neuroinflamm. 2018;5:e453.
   PubMed Web of Science ®Google Scholar
• Klink DT, van Elburg RM, Schreurs MW, et al. Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin Dev Immunol. 2008;2008:271363.
   PubMedGoogle Scholar
• Vaidyanathan A, McKeever K, Anand B, et al. Developmental immunotoxicology assessment of rituximab in cynomolgus monkeys. Toxicol Sci. 2011;119:116–125.
   PubMed Web of Science ®Google Scholar
• Bragnes Y, Boshuizen R, de Vries A, et al. Low level of rituximab in human breast milk in a patient treated during lactation. Rheumatology. 2017;56:1047–1048.
   PubMed Web of Science ®Google Scholar
• Hurley WL, Theil PK. Perspectives on immunoglobulins in colostrum and milk. Nutrients. 2011;3:442–474.
   PubMed Web of Science ®Google Scholar
• Cree BA. Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - Commentary. Mult Scler. 2018;24:1161–1162.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Saag K, Cascino MD, et al. Long-term safety of rituximab in rheumatoid arthritis: analysis from the SUNSTONE registry. Arthritis Care Res (Hoboken). 2018. doi: 10.1002/acr.23781. [Epub ahead of print] PubMed PMID: 30295434.
   PubMedGoogle Scholar
• Williams ME, Hong F, Gascoyne RD, et al. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: eastern cooperative oncology group protocol E4402. Br J Haematol. 2016;173:867–875.
   PubMed Web of Science ®Google Scholar
• Glaser A, Stahmann A, Meissner T, et al. Multiple sclerosis registries in Europe - an updated mapping survey. Mult Scler Relat Disord. 2018;27:171–178.
   PubMedGoogle Scholar